Based on the ANI Pharmaceuticals Inc stock forecast from 6 analysts, the average analyst target price for ANI Pharmaceuticals Inc is USD 87.00 over the next 12 months. ANI Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of ANI Pharmaceuticals Inc is Slightly Bearish, which is based on 3 positive signals and 7 negative signals. At the last closing, ANI Pharmaceuticals Inc’s stock price was USD 66.99. ANI Pharmaceuticals Inc’s stock price has changed by +0.06% over the past week, +10.51% over the past month and -0.89% over the last year.
No recent analyst target price found for ANI Pharmaceuticals Inc
No recent average analyst rating found for ANI Pharmaceuticals Inc
Company Overview ANI Pharmaceuticals Inc
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. It markets, sells, and distributes its products through wholesalers, retail market chains, distributors and specialty pharmacies, group purchasing organizations, specialty pharmacies, hospitals, clinics, and physicians. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota. Read Less
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ p...Read More
Frequently Asked Questions About ANI Pharmaceuticals Inc (ANIP) Stock
Based on ratings from 6 analysts ANI Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 8 buy, sell and hold ratings.
Unfortunately we do not have enough data on ANIP's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for ANIP is USD 87.00 over the next 12 months. The maximum analyst target price is USD 94 while the minimum anlayst target price is USD 80.
ANIP stock's Price/Earning ratio is 49.06.
Our analysis grades ANIP stock's Price / Earning ratio at F. This means that ANIP stock's Price/Earning ratio is above 64% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this ANIP may be a overvalued for its sector.
The last closing price of ANIP's stock was USD 66.99.
The most recent market capitalization for ANIP is USD 1.40B.
Based on targets from 6 analysts, the average taret price for ANIP is projected at USD 87.00 over the next 12 months.
This means that ANIP's stock price may go up by +37.99% over the next 12 months.
We can't find any ETFs which contains ANI Pharmaceuticals Inc's stock.
As per our most recent records ANI Pharmaceuticals Inc has 897 Employees.
ANI Pharmaceuticals Inc's registered address is 210 Main Street West, Baudette, MN, United States, 56623.
You can get more information about it from ANI Pharmaceuticals Inc's website at https://www.anipharmaceuticals.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About ANI Pharmaceuticals Inc (ANIP) Stock
Based on ratings from 6 analysts ANI Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 8 buy, sell and hold ratings.
Unfortunately we do not have enough data on ANIP's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for ANIP is USD 87.00 over the next 12 months. The maximum analyst target price is USD 94 while the minimum anlayst target price is USD 80.
ANIP stock's Price/Earning ratio is 49.06.
Our analysis grades ANIP stock's Price / Earning ratio at F. This means that ANIP stock's Price/Earning ratio is above 64% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this ANIP may be a overvalued for its sector.
The last closing price of ANIP's stock was USD 66.99.
The most recent market capitalization for ANIP is USD 1.40B.
Based on targets from 6 analysts, the average taret price for ANIP is projected at USD 87.00 over the next 12 months.
This means that ANIP's stock price may go up by +37.99% over the next 12 months.
We can't find any ETFs which contains ANI Pharmaceuticals Inc's stock.
As per our most recent records ANI Pharmaceuticals Inc has 897 Employees.
ANI Pharmaceuticals Inc's registered address is 210 Main Street West, Baudette, MN, United States, 56623.
You can get more information about it from ANI Pharmaceuticals Inc's website at https://www.anipharmaceuticals.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ANIP !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
